Гормонотерапия в акушерстве и гинекологии. Иллюзии и реальность

Pincus G., et al. Fertility control with oral medication. Am. J. Obstet. Gynecol., 1958; 75:1333–1346.

Pintiaux A., et al. Gynecological uses of a new class of steroids: the selective progesterone receptor modulators. Gynecol. Endocrinol., 2009; 25 (2):67–73.

Piotrowski J. Experimental investigations on the effect of progesterone on embryonal development. Part II. Investigations carried out on rabbits. Folia Biol. (Krakow), 1968a; 16:335–342.

Piotrowski J. The effect of progesterone on the foetal development of rats on the Wistar strain. Part 3. Folia Biol. (Krakow), 1968b; 16:343–353.

Pitts C. J., Kearns A. E. Update on Medications With Adverse Skeletal Effects. Mayo Clin. Proc., 2011; 86 (4):338–343.

Pointis G., et al. Ef fect of maternal progesterone exposure on fetal testosterone in mice. Biol. Neonate, 1984; 45:203–208.

Pointis G., et al. Effect of natural progesterone treatment during pregnancy on fetal testosterone and sexual behavior of the male offspring in the mouse. Dev. Pharmacol. Ther., 1987; 10:385–392.

Polednak A. P., Janerich D. T. Maternal characteristics and hypospadias: a case-control study. Teratology, 1983; 28:67–73.

Polgar B, et al. Urinary progesterone-induced blocking factor concentration is related to pregnancy outcome. Biol Reprod 2004;71:1699–1705.

Pollow K., et al. Gestodene: a novel synthetic progestin; characterization of binding to receptor and serum proteins. Contraception, 1989; 40:325–341.

Polson D. W., et al. Vaginal progesterone as luteal phase support in an IVF/GIFT programme. Eur. J. Obstet. Gynecol. Reprod. Biol., 1992; 46:35–38.

Ponnampalam A. P., et al. Molecular classification of human endometrial cycle stages by transcriptional profiling. Mol. Hum. Reprod.,2004; 10:879–893.

Porter T. F., Scott J. R. Evidence-based care of recurrent miscarriage. Best Pract. Res. Clin. Obstet. Gynecol., 2005; 19:85–101.

Potdar N., Konje J. C. The endocrinological basis of recurrent miscarriage. Curr. Opin. Obstet. Gynecol., 2005; 17:424–428.

Potischman N., et al. Pregnancy hormone concentrations across ethnic groups: implications for later cancer risk. Cancer Epidemiol. Biomarkers Prev., 2005; 14 (6):1514–1520.

Pouly J. L., et al. Luteal support after invitro fertilization: Crinone 8 %, a sustained release vaginal progesterone gel, versus Utrogestan, an oral micronized progesterone. Hum. Reprod., 1996; 11:2085–2089.

Pritts E. A., Atwood A. K. Luteal phase support in infertility treatment: a meta-analysis of the randomized trials. Hum. Reprod., 2002; 17:2287–2299.

Proctor A., et al. Effect of progesterone supplementation in early pregnancy on the pregnancy outcome after in vitro fertilization. Fertil. Steril., 2006; 85:1550–1552.

Progesterone. National Toxicology Program, Department of Health and Human Services.Report on Carcinogens, Twelfth Edition, 2011.

Publicover S., Barratt C. Progesterone’s gateway into sperm. Nature, 2011; 471:313–314.

Publicover S. J., Barratt C. L. R. Sperm motility: things are moving in the lab! Molecular Human Reproduction, 2011; 17 (8):453–456.

Qi H., et al. All four CatSper ion channel proteins are required for male fertility and sperm cell hyperactivated motility. Proc. Natl. Acad. Sci. USA, 2007; 104:1219–1223.

Quack K. C., et al. Leukocyte activation in the decidua of chromosomally normal and abnormal fetuses from women with recurrent abortion. Hum. Reprod., 2001; 16:949–955.

Raber L. Steroid industry honored. ACS News, 1999; 77:78–80.

Radulesco J. C. Dydrogesterone in treatment of hypohormonal pregnancy. Mars. Med., 1970; 107:191–196.

Raghupathy R., et al. Cytokine production by maternal lymphoctes during normal human pregnancy and in unexplained recurrent spontaneous abortion. Hum. Reprod., 2000; 15:713–718.

Raghupathy R., et al. Modulation of cytokine production by dydrogesterone in lymphocytes from women with recurrent miscarriage. Br. J. Obstet. Gynecol., 2005; 112:1096–1101.

Raghupathy R. Th1-type immunity is incompatible with successful pregnancy. Immunol. Today, 1997; 18:478–482.

Ragusa A., et al. Progesterone supplement in pregnancy: an immunologic therapy? Lupus, 2004; 13:639–642.

Rai R., et al. Recurrent miscarriage — an aspirin a day? Hum. Reprod., 2000; 15:2220–2223.

Rajaram R. D., Brisken C. Paracrine signaling by progesterone. Mol. Cel. Endocrinol., 2012; 357:80–90.

Ralt D., et al. Chemotactic and chemokinesis of human spermatozoa to follicular factors. Biol. Reprod., 1994; 50:774–785.

Ralt D., et al. Sperm attraction to a follicular factor (s) correlates with human egg fertilizability. Proc. Natl. Acad. Sci. USA, 1991; 88:2840–2844.

Raman-Wilms L., et al. Fetal genital effects of first-trimester sex hormone exposure: a metaanalysis. Obstet. Gynecol., 1995; 85:141–149.

Rapkin A. J., et al. Relationships among self-rated Tanner staging, hormones, and psychosocial factors in health female adolescents. J. Pediatr. Adolesc. Gynecol., 2006; 19:181–7.

Rapkin A. J. YAZ in the treatment of premenstrual dysphoric disorder. J. Reprod. Med., 2008; 53:729–741.